Newron Pharmaceuticals (NWRN)

Executive Summary

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. More Details


Trading at 58.8% below our estimate of its fair value

Revenue is forecast to grow 47.25% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Does not have a meaningful market cap (CHF37M)

Snowflake Analysis

Adequate balance sheet and fair value.

Search for a company to compare.